Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

J&J Touts its Pharma R&D Efforts for China

publication date: May 24, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Janssen Pharmaceutical Companies, a division of Johnson & Johnson, did something this week that big pharmas haven't done very often in the last few years: it bragged about its recent drug discovery success and made predictions about its future progress. The company said it had four new medical entities awaiting approval in China along with four line extensions. It expects to file an additional nine NMEs and six line extensions for approval by 2017. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors